[go: up one dir, main page]

NO20061045L - Imidazolderivater - Google Patents

Imidazolderivater

Info

Publication number
NO20061045L
NO20061045L NO20061045A NO20061045A NO20061045L NO 20061045 L NO20061045 L NO 20061045L NO 20061045 A NO20061045 A NO 20061045A NO 20061045 A NO20061045 A NO 20061045A NO 20061045 L NO20061045 L NO 20061045L
Authority
NO
Norway
Prior art keywords
imidazole
disorders
general formula
well
background
Prior art date
Application number
NO20061045A
Other languages
English (en)
Inventor
Sabine Kolczewski
Bernd Buettelmann
Georg Jaeschke
Eric Vieira
Richard Hugh Phillip Porter
Simona Maria Ceccarelli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20061045L publication Critical patent/NO20061045L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår imidazolderivater med den generelle formel hvor R1, R2, R3, R4, X og Y er som definert her, en fremgangsmåte for fremstilling derav, deres anvendelse for behandling eller forhindring av metabotropiske glutamatreseptormedierte lidelser, deres anvendelse for fremstilling av medikamenter for behandling av slike lidelser, samt farmasøytiske preparater inneholdende dem.
NO20061045A 2003-09-04 2006-03-03 Imidazolderivater NO20061045L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019604 2003-09-04
PCT/EP2004/009558 WO2005023795A1 (en) 2003-09-04 2004-08-27 Imidazole derivatives

Publications (1)

Publication Number Publication Date
NO20061045L true NO20061045L (no) 2006-03-31

Family

ID=34224067

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061045A NO20061045L (no) 2003-09-04 2006-03-03 Imidazolderivater

Country Status (21)

Country Link
US (2) US7452909B2 (no)
EP (1) EP1831193B1 (no)
JP (1) JP4490423B2 (no)
KR (2) KR100893957B1 (no)
CN (1) CN1875016B (no)
AR (1) AR045548A1 (no)
AT (1) ATE427945T1 (no)
AU (1) AU2004270352B2 (no)
BR (1) BRPI0414148A (no)
CA (1) CA2537826C (no)
CO (1) CO5650235A2 (no)
DE (1) DE602004020525D1 (no)
ES (1) ES2321408T3 (no)
IL (1) IL173911A (no)
MX (1) MXPA06002453A (no)
NO (1) NO20061045L (no)
RU (1) RU2345074C2 (no)
SG (1) SG146627A1 (no)
TW (1) TWI290138B (no)
WO (1) WO2005023795A1 (no)
ZA (1) ZA200601865B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8204149B2 (en) 2003-12-17 2012-06-19 Qualcomm Incorporated Spatial spreading in a multi-antenna communication system
US8169889B2 (en) 2004-02-18 2012-05-01 Qualcomm Incorporated Transmit diversity and spatial spreading for an OFDM-based multi-antenna communication system
US8923785B2 (en) 2004-05-07 2014-12-30 Qualcomm Incorporated Continuous beamforming for a MIMO-OFDM system
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
ATE397601T1 (de) * 2004-06-01 2008-06-15 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
US7978649B2 (en) 2004-07-15 2011-07-12 Qualcomm, Incorporated Unified MIMO transmission and reception
US8543070B2 (en) 2006-04-24 2013-09-24 Qualcomm Incorporated Reduced complexity beam-steered MIMO OFDM system
PT2125779T (pt) 2006-12-21 2016-07-19 Hoffmann La Roche Polimorfos de um antagonista de um recetor de mglur5
WO2009097414A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Use of imidazolylalkyl-pyridines for the treatment of addictive disorders
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU644802B2 (en) 1989-06-30 1993-12-23 E.I. Du Pont De Nemours And Company Substituted imidazoles
CA2356838A1 (en) * 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds and medicinal use thereof
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
ATE495168T1 (de) * 2003-06-12 2011-01-15 Hoffmann La Roche Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
CA2537826C (en) 2012-04-17
EP1831193B1 (en) 2009-04-08
AU2004270352B2 (en) 2011-02-24
ATE427945T1 (de) 2009-04-15
RU2006110537A (ru) 2007-10-10
MXPA06002453A (es) 2006-06-20
US7452909B2 (en) 2008-11-18
SG146627A1 (en) 2008-10-30
CN1875016A (zh) 2006-12-06
CO5650235A2 (es) 2006-06-30
KR20060037460A (ko) 2006-05-03
BRPI0414148A (pt) 2006-10-31
KR20070113325A (ko) 2007-11-28
US20090018171A1 (en) 2009-01-15
RU2345074C2 (ru) 2009-01-27
EP1831193A1 (en) 2007-09-12
IL173911A (en) 2012-07-31
ZA200601865B (en) 2007-09-26
DE602004020525D1 (en) 2009-05-20
CN1875016B (zh) 2011-06-01
TWI290138B (en) 2007-11-21
US20050054686A1 (en) 2005-03-10
JP4490423B2 (ja) 2010-06-23
IL173911A0 (en) 2006-07-05
US7964620B2 (en) 2011-06-21
CA2537826A1 (en) 2005-03-17
KR100811898B1 (ko) 2008-03-10
TW200517382A (en) 2005-06-01
KR100893957B1 (ko) 2009-04-20
AU2004270352A1 (en) 2005-03-17
WO2005023795A1 (en) 2005-03-17
ES2321408T3 (es) 2009-06-05
AR045548A1 (es) 2005-11-02
JP2007504188A (ja) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20066055L (no) Pyridinderivater
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20075749L (no) 1H-Quinazoline-2,4-diones and their use as ampa-receptor ligands
NO20020925D0 (no) N-heterosykliske derivater som NOS-inhibitorer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20055688L (no) Organiske forbindelser
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
EA200601065A1 (ru) Производные имидазола, способы их получения и применения
NO20064160L (no) Nye azaibicykliske forbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application